Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Users Online: 1602


Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Advertise Contacts Login 
Year : 2013  |  Volume : 54  |  Issue : 5  |  Page : 289-294

Recombinant activated factor VII in post partum haemorrhage

1 Department of Obstetrics and Gynecology, Air Force Hospital, Jorhat, India
2 Department of Obstetrics and Gynecology, Command Hospital (AF) Bangaluru, India
3 Department of Obstetrics and Gynecology, Army Hospital (R and R) Delhi, India
4 Department of Obstetrics and Gynecology, Military Hospital, Meerut, Uttar Pradesh, India
5 Department of Obstetrics and Gynecology, Sikkim Manipal Medical College, Gangtok, Sikkim, India

Correspondence Address:
Navneet Magon
Obstetrician-Gynaecologist and Endoscopic Surgeon, Head, Department of Obstetrics and Gynecology, Air Force Hospital, Jorhat, Assam
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0300-1652.122328

Rights and Permissions

Post-partum haemorrhage (PPH) is a life-threatening obstetric complication and the leading cause of maternal death. Any bleeding that results in or could result in haemodynamic instability, if untreated, must be considered as PPH. There is no controversy about the need for prevention and treatment of PPH. The keystone of management of PPH entails first, non-invasive and nonsurgical methods and then invasive and surgical methods. However, mortality remains high. Therefore, new advancements in the treatment are most crucial. One such advancement has been the use of recombinant activated factor VII (rFVIIa) in PPH. First used 12 years back in PPH, this universal haemostatic agent has been effectively used in controlling PPH. The best available indicator of rFVIIa efficacy is the arrest of haemorrhage, which is judged by visual evidence and haemodynamic stabilization. It also reduces costs of therapy and the use of blood components in massive PPH. In cases of intractable PPH with no other obvious indications for hysterectomy, administration of rFVIIa should be considered before surgery. We share our experience in a series of cases of PPH, successfully managed using rFVIIa.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded256    
    Comments [Add]    
    Cited by others 4    

Recommend this journal